Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02798406
Recruitment Status : Active, not recruiting
First Posted : June 14, 2016
Last Update Posted : March 22, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
DNAtrix, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2020
  Estimated Study Completion Date : June 2021